Bryan Neth, MD, PhD

Neuro-Oncology + Behavioral Neurology @mayoclinic | @mayoneurores + @WakeForest + @floridastate alum | Science. Art. Flavor. | Views are my own

[Eytan Ruppin, MD, PhD @EytanRuppin]

🚨 Out today in Cell! @CellCellPress

Path2Space: #AI that predicts spatial transcriptomics (ST) from H&E pathology, enabling spatial biomarker discovery in #BreastCancer at scale.

📄 https://t.co/GtrmH9zIDs

🧵1/8

[Divyanshu Dubey @Div_Dubey]

Grateful for our team effort featured by Mayo Clinic News Network—developing a blood test to detect germ cell tumors missed by standard markers.
https://t.co/HR7nFfaJJa

[Danny Arends @DannyArends]

Our paper in @Nature today 🥳 We tracked 6,438 mice from puberty to death and mapped the genetics of *when* you die, not just whether a gene associates with lifespan.

https://t.co/EoeexqJoHk

59 loci. Two decades of data. Thread 👇

#Longevity #Aging #Genetics #Healthspan

[gelareh-zadeh @gelarehzadeh]

Honored to have a @NatRevClinOncol publication on the work we & colleagues have done on #meningiomas
Research & discoveries improving #care #clinicaltrials
@ICOMeningioma @MeningiomaBot
RT 🙏🏻 @mayoclinic @MayoRadOnc @MayoCancerCare @MayoClinicNeuro
Thanking all #collaborators

[Alberto Vogrig @Vogrig_Alberto]

Why do only some cancer patients develop #paraneoplastic neurological syndromes (PNS)? 🧠
This review explores the immune mechanisms behind PNS and how tumor genetics & immune tolerance shape risk. Kudos to @AKunchok. Open access link: https://t.co/glF1CAIhn5

[PDBrown @PDBrownOnc]

Should we treat higher SRS doses for brainstem mets (than the typical lower doses used)?
Tumor control probability MODELING:
1 Yr 90%LC 18.9 Gy/1, 25.7/3, 28.6/5
2 Yr 90%LC 20.5 Gy/1, 28.2/3, 31.5/5
https://t.co/mipCmC609f

[PDBrown @PDBrownOnc]

Editorial CATNON IDHmt Grade 3 Astrocytoma
· NO benefit concurrent temozolomide
· Sig benefit w/adjuvant TMZ
· MGMT NOT prognostic
· Poor prog CDKN2A/B homo deletion, PDGFRA amp, methy profile
https://t.co/e8wGebVHFI

[PDBrown @PDBrownOnc]

What is the long term control Sporadic Vestibular Schwannoma after radiosurgery?
LC 5, 10, & 15 years 96%, 92%, & 91%
13% pseudoprogression median time 0.5 yrs (only 4% >5yr after SRS) https://t.co/x4MHXTUNC9

[nature @Nature]

For decades, researchers have noted that cancer and Alzheimer’s disease are rarely found in the same person

https://t.co/rgYalgRdfi

[Journal of Neuro-Oncology @JNeurooncol]

Gonzalez-Aponte et al. reported circadian rhythms in MGMT promoter methylation and protein levels in GBM, with peaks at midday and CT4, respectively, predicting time-of-day differences in temozolomide efficacy. #JNO

Read more:https://t.co/2eDZ6vL8fo

[Mayo Florida AutoImmune Neurology Group @Mayo_AING]

Also this came out today!

https://t.co/uN3TJQ3AVc

[PDBrown @PDBrownOnc]

Cognitive recovery after radiation brain mets meta-analysis
· 1/3 cognitive recovery @6mo after initial decline
· Recovery more likely if SRS or HA-WBRT compared to WBRT
https://t.co/S7aeKaiHAA

[Nir Lipsman @DrNirLipsman]

A decade after our world-first BBB opening for #GBM, our newest trial shows FUS is safe, well-tolerated, with signals of benefit.

A major milestone for a devastating illness.

Grateful to @INSIGHTEC, @FUSFoundation, our donors, and brave patients.

https://t.co/eoBYfieJQR

[Lyell Jones MD @LyellJ]

Coming soon, our first ever issue dedicated to…

[Bryan Neth, MD, PhD @bryanneth]

Longevity science has hit the mainstream—but no one agrees on the science https://t.co/hDvo9Hrl9c

[Ian F. Parney MD PhD @IanParneyMDPhD]

This is a great description of what is was like for ⁦@BobbyMukkamala⁩, incoming AMA President and ENT surgeon, to have an awake craniotomy. ⁦@MayoClinicNeuro⁩ ⁦@MayoClinic⁩ https://t.co/907ljr5qGJ

[Marcus Pinto, MD, MS @MarcusVPinto]

When I have a new fellow or resident in our peripheral nerve clinic, I always teach them the importance of defining the neuropathy clinical syndrome. NCS/EMG are valuable, but the neurological exam is the most important (as it should be in neurology but many have forgotten).

This is the neuropathy clinical phenotype classification I find the most helpful:

- Isolated small fiber neuropathy
- Length-dependent peripheral neuropathy (or distal symmetric polyneuropathy)
- Multiple mononeuropathies
- Mononeuropathy
- Asymmetric neuropathy
- Polyradiculoneuropathy
- Plexopathy (brachial or lumbosacral, many times a radiculoplexus neuropathy)
- Sensory neuronopathy
- Motor neuronopathy

I always tell my trainees they don’t have to memorize the causes of each phenotype. If you define the syndrome correctly, you can ask Google or ChatGtp what are the most likely causes. 😊

Definitions 👇👇👇

#NeuropathyBites

1/x

[Mayo Florida AutoImmune Neurology Group @Mayo_AING]

Our new CASPR2 paper is out @ANA_journals 🤩

Headlines: Patients have neuropathic pain & fatigue as their main long term complaints which determine QoL. 😰

These are NOT immunotherapy responsive. 👩🏾‍⚕️💊

We also report other nuggets in this thread 🧵 ⬇️

https://t.co/rngFbpplVF

[Marcus Pinto, MD, MS @MarcusVPinto]

In celebration of the legendary career of Professor Peter J. Dyck, who officially retired last month, I kick off today this series with a hidden gem: The 10 P's in the characterization and differential diagnosis of peripheral neuropathy.

#NeuropathyClassics

#DyckPapers

1/

[Rosa Ritunnano @RRitunnano]

Instead of listing my publications, as the year draws to an end, I want to put pressure on the commonplace assumption that productivity must always increase. Good research is disruptive and thinking time is central to high quality scholarship and necessary for disruptive research